Navigation Links
Cure For Pompe Disease

Pompe disease is a rare inherited enzyme deficiency that destroys muscles and can kill infants at a very young age. Myozyme is a drug developed by Genzyme// to treat this disease. Genzyme, a biotechnology company in Cambridge, Mass said that it has spent more than $500 million since 1998 to develop Myozyme.

It has also received incentives provided by the federal government to develop medicines against such disease collectively called orphans disease. The drug after passing through a variety of tests and trails has won the federal approval to sell the drug in the market. Genzyme officials said that the dug Myozyme, would cost about $200,000 to $300,000 a year. The disease incidence is less than 10000 people and they are all grateful for Genzyme's drugs. Genzyme said that it will provide the drug free of cost to those who cannot pay for it. During the clinical trail from 2003-05 the drug was administered to 18 infants.

They all lived until they were at least 18 months old, or about a year after starting treatment, and most are still alive today. The warning on the drug label says that Myozyme can also cause life-threatening anaphylactic or allergic reactions. Dr. David Meeker, president of the Genzyme division that developed Myozyme said that a new blood test was offered to diagnose the disease rapidly which could lead to earlier treatment with better outcome. But further tests are necessary to determine the effect of the drug against Pompe disease that begins later in childhood or in adulthood.


'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Vitamins-The answer to Heart Disease?
3. Link between Constipation and Parkinsons Disease
4. Levels Of Blood Proteins May Help Heart Disease Care
5. New Drug PP188 Helps Sickle Cell Disease
6. Gene Treatment for Heart Disease
7. Legume Consumption Can Cut Heart Disease Risk
8. Link Between Infection And Heart Disease
9. Celiac Disease in Type 1 Diabetes
10. Shunt for Alzheimers Disease
11. High iron levels may cause Cardiovascular Disease in women
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you ... from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty ... ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, ... experience the freedom of recovery, they often feel shame for having struggled with an ... disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- ...
(Date:1/20/2017)... ... ... and Overseer at The House of Yahweh has posted a new publication this week pleading ... a time like no other and society needs to understand the only way to help ... want to sound like an old bible beater because religion has a bad rap these ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company based in ... children since the holiday season. , “It happens every year around this time,” ... and taking photos, which is the head-to-head gateway that lice need to spread.” , ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a very ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
Breaking Medicine Technology: